研究者業績

松浦 秀哲

Hideaki Matsuura

基本情報

所属
藤田医科大学 医療科学部 臨床教育連携ユニット 細胞機能解析学分野 准教授
(兼任)藤田医科大学病院 輸血部 副部長
学位
博士(医学)(藤田保健衛生大学)

researchmap会員ID
B000339755

論文

 47
  • Hiroki Doi, Hidehiko Akiyama, Taei Matsui, Yuko Abe, Sumie Fujii, Hideaki Matsuura, Yasuo Miura
    Anticancer research 46(6) 3067-3077 2026年6月  査読有り
    BACKGROUND/AIM: Andrographolide (Andro), a diterpene lactone from Andrographis paniculata, induces apoptosis via reactive oxygen species (ROS)-dependent mitochondrial dysfunction but achieves low plasma concentrations because of its lipophilicity. We investigated whether low-dose Andro potentiates the cytotoxicity of the mechanistically distinct agents cytarabine (Ara-C) and vincristine (VCR) in plasma cell neoplasm cell lines. MATERIALS AND METHODS: Human plasma cell neoplasm cell lines H929 and ARH77 were treated with Andro alone or in combination with Ara-C or VCR. Cell viability was assessed in dose- and time-response experiments, and pharmacologic interactions were quantified using the combination index (CI) method. Apoptosis was evaluated by Annexin V staining, and cell-cycle distribution was analyzed to examine mechanistic complementarity. RESULTS: Andro decreased viability in a dose- and time-dependent manner (IC50 at 48 h: 3.4 μM in H929; 7.5 μM in ARH77). Combining Andro with Ara-C or VCR further reduced viability; in H929 cells, all combination conditions yielded CI values <1.0, indicating synergy. Combination treatments markedly increased Annexin V-positive fractions, implicating apoptosis as a major contributor to enhanced cytotoxicity. While Andro alone did not appreciably alter cell-cycle profiles, it modestly influenced Ara-C- and VCR-associated changes in cell-cycle distribution, consistent with complementary mechanisms. CONCLUSION: Low-dose Andro strengthens Ara-C- and VCR-driven cytotoxic programs and provides a quantitative rationale for Andro-based combination strategies in plasma cell neoplasms and related hematologic malignancies.
  • Yohei Sakai, Hideaki Matsuura, Ryusei Ito, Kakeru Ishii, Anna Yoshimine, Rie Nakagawa, Yuya Ishihara, Shota Fujiki, Shoko Arakawa, Hiroki Doi, Sumie Fujii, Yasuo Miura
    British journal of haematology 2026年5月24日  査読有り責任著者
  • Yohei Sakai, Takato Ozeki, Hideaki Matsuura, Rie Nakagawa, Yuya Ishihara, Hiroki Doi, Yasuo Miura
    Transfusion medicine (Oxford, England) 2026年3月6日  査読有り責任著者
    BACKGROUND: Packed red blood cells (PRBC) are stored at 2°C-6°C to ensure quality. Improper temperature control during PRBC transport reduces the quality of downstream blood products and wastes PRBC units. This study evaluated the suitability of the BioBox LAB10 for in-hospital PRBC transport. METHODS: Temperatures of the box interior and simulated formulation were measured to assess cooling capabilities. Quality was evaluated by measuring red blood cell count, haemoglobin concentration, haematocrit, pH, potassium concentration, and ATP concentration of PRBC samples. The storage capacity, size, weight, and cost of the BioBox was compared with that of the ATR700. RESULTS: The BioBox cooled to ≤6°C within 14 min. PRBC temperature remained ≤6°C for approximately 19 h. None of the quality parameters, including ATP concentration, differed significantly between samples stored in the BioBox or in a refrigerator. The BioBox is smaller, lighter, and 84% less expensive than the ATR700, with an equivalent storage capacity. CONCLUSIONS: The BioBox effectively maintains temperature and PRBC quality during transport and provides a practical solution for in-hospital transport of blood for transfusion owing to its compact, lightweight design, and affordability.
  • 松浦 秀哲, 小嶋 俊介, 奥田 誠, 田中 朝志, 藤原 慎一郎, 松本 雅則, 日本輸血・細胞治療学会ガイドライン委員会
    日本輸血細胞治療学会誌 72(1) 11-16 2026年2月  査読有り筆頭著者
  • Hideaki Matsuura, Ayuna Yamada, Hiroki Doi, Sumie Fujii, Yasuo Miura
    Blood advances 2025年12月5日  査読有り筆頭著者責任著者

MISC

 128

書籍等出版物

 5

講演・口頭発表等

 17

共同研究・競争的資金等の研究課題

 3

その他

 2